Invivyd: High-Stakes Rebound Play in Viral Antibody Therapies Amidst Scientific and Commercial Uncertainty
Overview
Invivyd, Inc. is a clinical-stage biotech focusing on monoclonal antibodies to prevent severe viral diseases, chiefly targeting immunocompromised patients who do not respond well to vaccines. After rebranding from Adagio due to the obsolescence of its first-generation antibody, Invivyd now leads with PEMGARDA, which received FDA emergency use authorization for COVID-19 pre-exposure prophylaxis in patients with moderate to severe immunocompromise. The company’s strategy is to offer an antibody-based vaccine alternative in a niche critical for vulnerable populations. Leveraging its proprietary antibody discovery platform, Invivyd is building a pipeline that targets other major respiratory threats, including RSV and Long COVID, aiming to address pressing unmet needs and expand beyond its foundational COVID-19 focus.